US Stock MarketDetailed Quotes
ALT Altimmune
- 8.680
- +0.275+3.27%
Close Nov 22 16:00 ET
- 8.695
- +0.015+0.18%
Post 20:01 ET
617.36MMarket Cap-5528P/E (TTM)
8.840High8.280Low2.24MVolume8.420Open8.405Pre Close19.31MTurnover3.17%Turnover RatioLossP/E (Static)71.12MShares14.84052wk High4.63P/B612.78MFloat Cap2.76052wk Low--Dividend TTM70.60MShs Float978.000Historical High--Div YieldTTM6.66%Amplitude-1731.000Historical Low8.630Avg Price1Lot Size
About Altimmune Company
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Company Profile
SymbolALT
Company NameAltimmune
Listing DateOct 6, 2005
Founded1997
CEODr. Vipin K. Garg, PhD
MarketNASDAQ
Employees59
Fiscal Year Ends12-31
Address910 Clopper Road,Suite 201S
CityGaithersburg
ProvinceMaryland
CountryUnited States of America
Zip Code20878
Phone1-240-654-1450
Websitehttp://www.altimmune.com
Company Executives
- Name
- Position
- Salary
- Dr. Vipin K. Garg, PhD
- Director, President and Chief Executive Officer
- 5.48M
- Gregory L. Weaver
- Chief Financial Officer and Principal Accounting Officer
- --
- Raymond M. Jordt, M.B.A.
- Chief Business Officer
- 2.94M
- Dr. M. Scott Harris, M.D.
- Chief Medical Officer
- 2.24M
- Dr. M. Scot Roberts, PhD
- Chief Scientific Officer
- --
- Dr. Mitchel Sayare,PhD
- Chairman of the Board
- 119.68K
- Dr. Klaus O. Schafer, M.D.,M.P.H.
- Independent Director
- 104.68K
- Dr. Diane K. Jorkasky, M.D.
- Independent Director
- 95.68K
- John M. Gill
- Independent Director
- 103.68K
- Wayne Pisano
- Independent Director
- 108.68K
- Philip L. Hodges
- Independent Director
- 115.68K
- Dr. Catherine Angell Sohn, Pharm.D.
- Independent Director
- 273.47K
- Andrew Shutterly, M.S.
- Corporate Controller
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
